MXPA03010435A - Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. - Google Patents

Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.

Info

Publication number
MXPA03010435A
MXPA03010435A MXPA03010435A MXPA03010435A MXPA03010435A MX PA03010435 A MXPA03010435 A MX PA03010435A MX PA03010435 A MXPA03010435 A MX PA03010435A MX PA03010435 A MXPA03010435 A MX PA03010435A MX PA03010435 A MXPA03010435 A MX PA03010435A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
ppar
alpha
carboxylic acid
Prior art date
Application number
MXPA03010435A
Other languages
English (en)
Spanish (es)
Inventor
Hilpert Hans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03010435A publication Critical patent/MXPA03010435A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA03010435A 2001-05-15 2002-05-06 Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. MXPA03010435A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15
PCT/EP2002/004962 WO2002092084A1 (en) 2001-05-15 2002-05-06 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Publications (1)

Publication Number Publication Date
MXPA03010435A true MXPA03010435A (es) 2004-03-09

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010435A MXPA03010435A (es) 2001-05-15 2002-05-06 Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.

Country Status (38)

Country Link
US (1) US6642389B2 (https=)
EP (1) EP1392295B1 (https=)
JP (2) JP4330883B2 (https=)
KR (1) KR100654516B1 (https=)
CN (1) CN100356917C (https=)
AR (1) AR035892A1 (https=)
AT (1) ATE327753T1 (https=)
AU (1) AU2002342244B2 (https=)
BG (1) BG66316B1 (https=)
BR (1) BRPI0209821B1 (https=)
CA (1) CA2445145C (https=)
CY (1) CY1105160T1 (https=)
CZ (1) CZ20033037A3 (https=)
DE (1) DE60211891T2 (https=)
DK (1) DK1392295T3 (https=)
EC (1) ECSP034848A (https=)
EG (1) EG25755A (https=)
ES (1) ES2264482T3 (https=)
GT (1) GT200200085A (https=)
HR (1) HRP20030889B1 (https=)
HU (1) HU230224B1 (https=)
IL (2) IL158589A0 (https=)
JO (1) JO2282B1 (https=)
MA (1) MA27025A1 (https=)
ME (1) ME01310B (https=)
MX (1) MXPA03010435A (https=)
MY (1) MY136761A (https=)
NO (1) NO333833B1 (https=)
NZ (1) NZ529033A (https=)
PA (1) PA8544901A1 (https=)
PE (1) PE20021152A1 (https=)
PL (1) PL208074B1 (https=)
PT (1) PT1392295E (https=)
RU (1) RU2278859C2 (https=)
SI (1) SI1392295T1 (https=)
SK (1) SK287842B6 (https=)
WO (1) WO2002092084A1 (https=)
ZA (1) ZA200308538B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HUP0302397A3 (en) * 2000-05-26 2007-02-28 Nippon Shinyaku Co Ltd Heterocyclic compounds and pharmaceutical compositions containing them
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
ES2316736T3 (es) 2002-02-25 2009-04-16 Eli Lilly And Company Moduladores de receptores activados por proliferador de peroxisoma.
ES2350340T3 (es) * 2002-08-30 2011-01-21 F. Hoffmann-La Roche Ag Nuevos compuestos de 2-aril-tiazol como agonistas de pparalfa y ppargamma.
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
ES2319184T3 (es) * 2002-11-15 2009-05-05 Cadila Healthcare Limited Derivados de aralquil sustituidos.
ATE405560T1 (de) 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CN1875002B (zh) * 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
EP1682507A1 (en) * 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
JP4682192B2 (ja) 2004-05-03 2011-05-11 エフ.ホフマン−ラ ロシュ アーゲー 肝x受容体モジュレータとしてのインドリル誘導体
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N-芳丙烯酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
EP2100604B1 (en) * 2008-03-10 2012-07-04 Nestec S.A. Medium chain dicarboxylic acids and their derivates and metabolic disorders
AU2009246626A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
CN102265280A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于在收集设备上运行的结构化收集过程的实现、执行、数据收集和数据分析的管理方法和系统
PE20120421A1 (es) * 2009-01-23 2012-05-04 Hoffmann La Roche Composicion farmaceutica que comprende aleglitazar
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
ES2552310T3 (es) 2009-12-07 2015-11-27 F. Hoffmann-La Roche Ag Proceso para la obtención de derivados de ácido propiónico
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
MX2015002095A (es) 2012-09-12 2015-05-11 Hoffmann La Roche Formas solidas de acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxaz ol-4-il)-etoxi]benzo[b]tiofen-7-il}propionico y de sales del mismo.
EP3402482A1 (en) 2015-11-18 2018-11-21 H. Hoffnabb-La Roche Ag Aleglitazar for the treatment of diabetic kidney disease
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
CA3227149A1 (en) * 2021-08-13 2023-02-16 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
EP0903343B1 (en) 1997-09-19 2003-05-28 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
HUP0300857A3 (en) * 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes

Also Published As

Publication number Publication date
IL158589A (en) 2010-11-30
CN1509173A (zh) 2004-06-30
HUP0400992A2 (hu) 2004-08-30
SI1392295T1 (sl) 2006-10-31
MY136761A (en) 2008-11-28
EP1392295A1 (en) 2004-03-03
NO333833B1 (no) 2013-09-30
BG66316B1 (bg) 2013-04-30
JP2009138011A (ja) 2009-06-25
CA2445145C (en) 2008-10-14
RU2003134150A (ru) 2005-06-10
EG25755A (en) 2012-06-26
CZ20033037A3 (cs) 2004-06-16
KR100654516B1 (ko) 2006-12-05
HK1067534A1 (en) 2005-04-15
CN100356917C (zh) 2007-12-26
BRPI0209821B1 (pt) 2016-09-27
NO20035086L (no) 2003-11-14
SK13852003A3 (en) 2004-10-05
HRP20030889B1 (hr) 2011-10-31
EP1392295B1 (en) 2006-05-31
JP2004529174A (ja) 2004-09-24
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
ATE327753T1 (de) 2006-06-15
IL158589A0 (en) 2004-05-12
BR0209821A (pt) 2004-06-01
PA8544901A1 (es) 2003-01-24
ECSP034848A (es) 2003-12-24
DK1392295T3 (da) 2006-10-02
ES2264482T3 (es) 2007-01-01
JP4330883B2 (ja) 2009-09-16
CA2445145A1 (en) 2002-11-21
NZ529033A (en) 2005-06-24
WO2002092084A1 (en) 2002-11-21
HU230224B1 (hu) 2015-10-28
KR20030096397A (ko) 2003-12-24
HUP0400992A3 (en) 2007-11-28
US6642389B2 (en) 2003-11-04
BG108362A (bg) 2005-03-31
PT1392295E (pt) 2006-09-29
PL208074B1 (pl) 2011-03-31
CY1105160T1 (el) 2009-11-04
SK287842B6 (sk) 2011-12-05
US20030055265A1 (en) 2003-03-20
AU2002342244B2 (en) 2005-06-16
PE20021152A1 (es) 2003-02-07
GT200200085A (es) 2003-01-16
NO20035086D0 (no) 2003-11-14
AR035892A1 (es) 2004-07-21
DE60211891T2 (de) 2007-05-24
ZA200308538B (en) 2005-04-26
HRP20030889A2 (en) 2005-08-31
ME01310B (me) 2011-10-10
JO2282B1 (en) 2005-09-12
DE60211891D1 (de) 2006-07-06
MA27025A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
NZ514234A (en) N-cyanomethylamides as protease inhibitors
PT1147110E (pt) Derivados de pirazino (aza)-indol
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
SE0202462D0 (sv) Novel use
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
ATE357453T1 (de) Comt-inhibitoren
WO2003006443A3 (de) 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie
TW200407133A (en) Novel PPARα and PPARγ agonists
AU2003278667A1 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
SE0302756D0 (sv) Novel Compounds
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases
SE0201193D0 (sv) Novel use

Legal Events

Date Code Title Description
FG Grant or registration